Last update July 31, 2018
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Lisinopril in other languages or writings:
Lisinopril belongs to this group or family:
Main tradenames from several countries containing Lisinopril in its composition:
|Oral Bioavail.||25 (6 - 60)||%|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Lisinopril is an angiotensin-converting enzyme inhibitor (ACEI) used in the treatment of hypertension, heart failure and diabetic nephropathy and as prophylaxis after myocardial infarction.
Oral administration once a day.
Since the last update we have not found published data on its excretion in breastmilk.
Other compounds from the same group (ACEI) are not excreted in breastmilk in significant amounts, but until there is more information about this drug in relation to breastfeeding, safer known alternatives are preferable, especially during the neonatal period and in case of prematurity. (Anderson 2018, Hale 2017 p567, Malachias 2016, AEMPS 2017).
The protective role of breastfeeding against maternal hypertension has been proven (Park 2018)